Overview
Familial hemophagocytic lymphohistiocytosis (FHL), also known as familial erythrophagocytic lymphohistiocytosis or primary hemophagocytic lymphohistiocytosis, is a rare and life-threatening inherited disorder of the immune system. It belongs to a group of conditions called hemophagocytic lymphohistiocytosis (HLH), characterized by uncontrolled activation and proliferation of T lymphocytes and macrophages that infiltrate multiple organs. This excessive immune activation leads to widespread tissue damage and organ dysfunction. The disease primarily affects the hematologic, hepatic, neurological, and immune systems. Key clinical features include prolonged high fever, enlarged liver and spleen (hepatosplenomegaly), cytopenias (low blood cell counts affecting red blood cells, white blood cells, and platelets), elevated ferritin and triglycerides, low fibrinogen, and evidence of hemophagocytosis (macrophages engulfing blood cells) in the bone marrow, spleen, or lymph nodes. Neurological involvement is common and may include irritability, seizures, cranial nerve palsies, ataxia, and altered consciousness. Liver dysfunction with jaundice and coagulopathy may also occur. Without treatment, the disease is rapidly fatal. Several genetic subtypes have been identified: FHL type 2 (PRF1 gene), FHL type 3 (UNC13D gene), FHL type 4 (STX11 gene), and FHL type 5 (STXBP2 gene). These genes encode proteins essential for the cytotoxic function of natural killer cells and cytotoxic T lymphocytes. Treatment involves immunosuppressive and chemotherapeutic protocols, most commonly the HLH-94 or HLH-2004 protocols, which include dexamethasone, etoposide, and cyclosporine A. Intrathecal methotrexate may be used for central nervous system involvement. However, the only curative treatment is allogeneic hematopoietic stem cell transplantation (HSCT), which is recommended for all patients with confirmed familial forms of the disease.
Also known as:
Clinical phenotype terms— hover any for plain English:
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Infantile
Begins in infancy, roughly 1 month to 2 years old
Treatments
No FDA-approved treatments are currently listed for Familial hemophagocytic lymphohistiocytosis.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Familial hemophagocytic lymphohistiocytosis at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Familial hemophagocytic lymphohistiocytosis.
Community
No community posts yet. Be the first to share your experience with Familial hemophagocytic lymphohistiocytosis.
Start the conversation →Latest news about Familial hemophagocytic lymphohistiocytosis
1 articlesCaregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Familial hemophagocytic lymphohistiocytosis
What is Familial hemophagocytic lymphohistiocytosis?
Familial hemophagocytic lymphohistiocytosis (FHL), also known as familial erythrophagocytic lymphohistiocytosis or primary hemophagocytic lymphohistiocytosis, is a rare and life-threatening inherited disorder of the immune system. It belongs to a group of conditions called hemophagocytic lymphohistiocytosis (HLH), characterized by uncontrolled activation and proliferation of T lymphocytes and macrophages that infiltrate multiple organs. This excessive immune activation leads to widespread tissue damage and organ dysfunction. The disease primarily affects the hematologic, hepatic, neurological,
How is Familial hemophagocytic lymphohistiocytosis inherited?
Familial hemophagocytic lymphohistiocytosis follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Familial hemophagocytic lymphohistiocytosis typically begin?
Typical onset of Familial hemophagocytic lymphohistiocytosis is infantile. Age of onset can vary across affected individuals.
Which specialists treat Familial hemophagocytic lymphohistiocytosis?
9 specialists and care centers treating Familial hemophagocytic lymphohistiocytosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.